Betatalassemia intermediária e menor (pediatria)
Indução farmacológica da síntese da hemoglobina fetal
Terapia com hidroxiureia (hidroxicarbamida)
Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (abre nova janela)
Fonte: Hemoglobin 2014;38(1):44-8.
Indexado: PubMed 24144212
DOI: 10.3109/03630269.2013.845844
https://www.ncbi.nlm.nih.gov/pubmed/24144212 (abre nova janela)
Hydroxyurea in thalassemia intermedia--a promising therapy. (abre nova janela)
Fonte: Ann Hematol 2005;84(7):441-6.
Indexado: PubMed 15838670
DOI: 10.1007/s00277-005-1026-4
https://www.ncbi.nlm.nih.gov/pubmed/15838670 (abre nova janela)
Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (abre nova janela)
Fonte: J Clin Pathol 2010;63(2):147-50.
Indexado: PubMed 20154037
DOI: 10.1136/jcp.2009.070391
https://www.ncbi.nlm.nih.gov/pubmed/20154037 (abre nova janela)
Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (abre nova janela)
Fonte: Eur J Haematol 2009;82(3):213-8.
Indexado: PubMed 19077048
DOI: 10.1111/j.1600-0609.2008.01192.x
https://www.ncbi.nlm.nih.gov/pubmed/19077048 (abre nova janela)
Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. (abre nova janela)
Fonte: J Pediatr Hematol Oncol 2005;27(7):380-5.
Indexado: PubMed 16012328
https://www.ncbi.nlm.nih.gov/pubmed/16012328 (abre nova janela)
Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (abre nova janela)
Fonte: Eur J Haematol 2010;84(1):52-8.
Indexado: PubMed 19799627
DOI: 10.1111/j.1600-0609.2009.01356.x
https://www.ncbi.nlm.nih.gov/pubmed/19799627 (abre nova janela)
The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. (abre nova janela)
Fonte: Pediatr Hematol Oncol 2003;20(6):429-34.
Indexado: PubMed 14631615
https://www.ncbi.nlm.nih.gov/pubmed/14631615 (abre nova janela)
Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (abre nova janela)
Fonte: Ann N Y Acad Sci 2005;1054:250-6.
Indexado: PubMed 16339672
DOI: 10.1196/annals.1345.031
https://www.ncbi.nlm.nih.gov/pubmed/16339672 (abre nova janela)
Eritropoetina recombinante (isolada ou combinada com outros agentes)
Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (abre nova janela)
Fonte: Acta Haematol 2004;111(4):189-95.
Indexado: PubMed 15153710
DOI: 10.1159/000077551
https://www.ncbi.nlm.nih.gov/pubmed/15153710 (abre nova janela)
Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. (abre nova janela)
Fonte: Eur J Haematol 2013;91(6):522-33.
Indexado: PubMed 23927461
DOI: 10.1111/ejh.12182
https://www.ncbi.nlm.nih.gov/pubmed/23927461 (abre nova janela)
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (abre nova janela)
Fonte: Pediatr Ann 2008;37(5):339-46.
Indexado: PubMed 18543545
https://www.ncbi.nlm.nih.gov/pubmed/18543545 (abre nova janela)
Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. (abre nova janela)
Fonte: Br J Haematol 1995;90(2):341-5.
Indexado: PubMed 7794754
https://www.ncbi.nlm.nih.gov/pubmed/7794754 (abre nova janela)
Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (abre nova janela)
Fonte: Br J Haematol 2011;154(2):281-4.
Indexado: PubMed 21496003
DOI: 10.1111/j.1365-2141.2011.08617.x
https://www.ncbi.nlm.nih.gov/pubmed/21496003 (abre nova janela)
The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (abre nova janela)
Fonte: Blood Rev 2012;26 Suppl 1:S35-9.
Indexado: PubMed 22631042
DOI: 10.1016/S0268-960X(12)70011-5
https://www.ncbi.nlm.nih.gov/pubmed/22631042 (abre nova janela)
Outros agentes
Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia. (abre nova janela)
Fonte: Evid Based Complement Alternat Med 2009;6(2):141-51.
Indexado: PubMed 18955291
DOI: 10.1093/ecam/nem139
https://www.ncbi.nlm.nih.gov/pubmed/18955291 (abre nova janela)
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. (abre nova janela)
Fonte: Br J Haematol 2013;161(4):587-93.
Indexado: PubMed 23530969
DOI: 10.1111/bjh.12304
https://www.ncbi.nlm.nih.gov/pubmed/23530969 (abre nova janela)
Butyric acid: what is the future for this old substance? (abre nova janela)
Fonte: Swiss Med Wkly 2012;142:w13596.
Indexado: PubMed 22674349
DOI: 10.4414/smw.2012.13596
https://www.ncbi.nlm.nih.gov/pubmed/22674349 (abre nova janela)